Evidence map›Paper›PMID 39679163›Full record

ArticleCrohn's & colitis 3602024

Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab Therapy.

Rochelle Wong, Paris Charilaou, Amy Hemperly, Lihui Qin, Yushan Pan, Prerna Mathani, Randy Longman, Brigid S Boland, Parambir S Dulai, Ariela K Holmer and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Crohn's & colitis 360, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rochelle WongDivision of Gastroenterology and Liver Diseases, Department of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0003-3326-3360
Paris CharilaouDepartment of Medicine, Section of Gastroenterology and Hepatology, Wake Forest Medical School, Charlotte, NC, USA.ORCID https://orcid.org/0000-0002-5512-4225
Amy HemperlyDivision of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Lihui QinDepartment of Pathology, Weill Cornell Medicine, New York, NY, USA.
Yushan PanDivision of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Prerna MathaniDivision of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Randy LongmanDivision of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Brigid S BolandDivision of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Parambir S DulaiDivision of Gastroenterology and Hepatology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Ariela K HolmerDivision of Gastroenterology, Department of Medicine, NYU Langone Health, New York, NY, USA.
Dana LukinDivision of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Siddharth SinghDivision of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Mark A ValasekDepartment of Pathology, University of California, San Diego, La Jolla, CA, USA.
William J SandbornDivision of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Ellen ScherlDivision of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Niels Vande CasteeleDivision of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.ORCID https://orcid.org/0000-0003-0854-0274
Robert BattatDepartment of Gastroenterology, University of Montreal, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0002-7421-9764

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: No models predict future outcomes in inflammatory bowel disease (IBD) patients receiving maintenance infliximab therapy. We created a predictive model for unfavorable outcomes. Methods: Adult patients with IBD receiving maintenance infliximab therapy at 2 centers with matched serum infliximab concentrations and blinded histologic scores (Robarts Histopathologic Index [RHI]) were included. The primary endpoint was an unfavorable outcome of active objective inflammation or need for IBD-related surgery or hospitalization at 6-18 months follow-up. Internal variables were identified using univariable analyses, modeling used multivariable analysis, and performance was assessed (area under receiver-operating curve [AUC]) and externally validated. Results: In 81 patients, 40.7% developed unfavorable outcomes at follow-up. Infliximab concentration <9.3 µg/mL (odds ratio [OR] 5.3, Conclusions: Using unbiased variable selection, a 2-predictor model using infliximab concentrations and histology identified IBD patients on maintenance infliximab therapy at high risk of future unfavorable outcomes. For practical applicability, infliximab concentrations alone performed similarly well.

Indexed as

endoscopyinfliximabmaintenancepathologypredictive model

Identifiers

PMID39679163
PMCPMC11645457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.